Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $50.40M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -24.9% | +392.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -24.9% over three years. Forward estimates point to Revenue at +392.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ovid Therapeutics Inc. NASDAQ:OVID | $556.60M | $2.85 | Not rated | -7.1 | +82.81% |
Shattuck Labs, Inc. NASDAQ:STTK | $463.68M | $4.62 | Not rated | -10.9 | +132.14% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $178.44M | $3.13 | Not rated | -2.6 | +49.28% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $160.57M | $3.86 | Not rated | 1.4 | +58.37% |
MacroGenics, Inc. NASDAQ:MGNX | $148.42M | $2.33 | Not rated | -3.6 | +39.44% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $122.44M | $1.72 | Not rated | -2.1 | +2.26% |
Coya Therapeutics, Inc. NASDAQ:COYA | $70.14M | $2.99 | Not rated | -3.9 | -48.53% |
Pliant Therapeutics, Inc. NASDAQ:PLRX | $50.14M | $0.81 | Not rated | -0.6 | -46.02% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $45.89M | $0.73 | Not rated | -4.0 | -74.53% |
Context Therapeutics Inc. NASDAQ:CNTX | $17.78M | $0.19 | Not rated | -1.5 | -40.77% |
Continue the stock analysis
Jump to another research area for this company.